Renal Clear Cell Carcinoma disease: Malacards - Research Articles, Symptoms, Drugs, Genes, Clinical Trials

MCID: RNL003 MIFTS: 56	Renal Clear Cell Carcinoma malady Categories: Genetic diseases, Nephrological diseases, Cancer diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptom Drugs Download this MalaCard Expand all tables

Aliases & Classifications for Renal Clear Cell Carcinoma

Sources:
¹⁰Disease Ontology, ⁴⁷Novoseek, ¹²DISEASES, ⁶⁵UMLS, ⁵¹Orphanet, ²⁴GTR, ³⁶MeSH, ⁴²NCIt, ⁵⁹SNOMED-CT, ²⁸ICD10 via Orphanet
See all MalaCards sources

Aliases & Descriptions for Renal Clear Cell Carcinoma:

Name: Renal Clear Cell Carcinoma ¹⁰ ⁴⁷ ¹²

Clear-Cell Metastatic Renal Cell Carcinoma ¹⁰ ⁶⁵

Conventional Renal Cell Carcinoma ¹⁰ ⁶⁵

Clear Cell Renal Carcinoma ⁵¹ ²⁴

Clear Cell Renal Cell Adenocarcinoma ⁵¹

Conventional Renal Cell Carcinoma ¹⁰

Clear Cell Renal Cell Carcinoma ⁵¹

Clear Cell Carcinoma of Kidney ¹⁰

Clear Cell Kidney Carcinoma ¹⁰

Adenocarcinoma, Clear Cell ⁶⁵

Clear Cell Adenocarcinoma ⁵¹

Ccrcc ⁵¹

Classifications:

MalaCards categories:
Global: Genetic diseases, Cancer diseases, Rare diseases
Anatomical: Nephrological diseases

See all MalaCards categories (disease lists)

ICD10: ²⁸

Neoplasms

Malignant neoplasms of urinary tract

Malignant neoplasm of kidney, except renal pelvis

Orphanet: ⁵¹

Rare renal diseases

Rare tumors

External Ids:

Disease Ontology¹⁰ DOID:4467

MeSH³⁶ D002292

NCIt⁴² C4033

SNOMED-CT⁵⁹ 188251003, 254915003, 41607009

Orphanet⁵¹ 319276

ICD10 via Orphanet²⁸ C64

UMLS⁶⁵ C0279702, C2931852

Summaries for Renal Clear Cell Carcinoma

Sources:
¹⁰Disease Ontology, ³³MalaCards
See all MalaCards sources

Disease Ontology:¹⁰ A renal cell carcinoma that has material basis in cells that appear very pale or clear when examined under microscope.

MalaCards based summary: Renal Clear Cell Carcinoma, also known as clear-cell metastatic renal cell carcinoma, is related to hemangioblastoma and renal cell carcinoma, and has symptoms including flank painand flank pain. An important gene associated with Renal Clear Cell Carcinoma is HNF1A (HNF1 Homeobox A), and among its related pathways are VEGF ligand-receptor interactions and HIF-1-alpha transcription factor network. Affiliated tissues include kidney, endothelial and liver, and related mouse phenotypes are embryo and muscle.

Related Diseases for Renal Clear Cell Carcinoma

Sources:
²⁰GeneCards, ¹⁹GeneAnalytics
See all MalaCards sources

Diseases in the Renal Cell Carcinoma family:

Hereditary Renal Cell Carcinoma	renal clear cell carcinoma
Familial Renal Cell Carcinoma	Renal Cell Carcinoma 4

Diseases related to Renal Clear Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)

id	Related Disease	Score	Top Affiliating Genes
1	hemangioblastoma	30.5	CA9, HIF1A, VEGFA, VHL
2	renal cell carcinoma	25.1	BIRC5, CA9, CUL2, FHIT, HIF1A, HNF1A
3	clear cell adenocarcinoma	21.7	BIRC5, CA9, CUL2, FHIT, HIF1A, HNF1A
4	hereditary conventional renal cell carcinoma	12.2
5	clear cell renal cell carcinoma	11.6
6	multilocular cystic renal cell carcinoma	11.2
7	hereditary clear cell renal cell carcinoma	11.2
8	iodine antenatal infection	10.9	HIF1A, VEGFA
9	g6pc3 deficiency	10.8	HIF1A, VHL
10	bladder urachal squamous cell carcinoma	10.8	KDR, VEGFA
11	noninvasive malignant thymoma	10.7	HIF1A, MUC1
12	hypospadias-hypertelorism-coloboma and deafness syndrome	10.7	KDR, VEGFA, VHL
13	acute myeloblastic leukemia with maturation	10.7	HIF1A, VEGFA, VHL
14	microscopic colitis	10.7	HIF1A, VEGFA
15	chronic angina	10.7	SETD2, VHL
16	autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to kiaa0226 deficiency	10.7	KRT7, VHL
17	von hippel-lindau syndrome	10.7	HIF1A, VEGFA, VHL
18	albinism, oculocutaneous, type ia	10.7	HIF1A, KDR, VEGFA
19	uterine ligament serous adenocarcinoma	10.7	BIRC5, HIF1A, VEGFA
20	chronic venous insufficiency	10.7	HIF1A, KDR, VEGFA
21	hematologic cancer	10.6	HIF1A, KDR, VEGFA
22	retinal vein occlusion	10.6	HIF1A, SETD2, VEGFA
23	malignant ovarian brenner tumor	10.6	MUC1, VIM
24	citrullinemia, adult-onset type ii	10.6	HIF1A, KDR, VEGFA
25	absence of fingerprints congenital milia	10.6	MUC1, VIM
26	cervical adenocarcinoma	10.6	KRT7, MME
27	large intestine adenoma	10.6	KRT7, MTOR
28	anovulation	10.6	MUC1, VIM
29	scrotal angioma	10.6	KRT7, MME
30	papillary adenocarcinoma	10.5	BIRC5, MUC1, VEGFA
31	pancreatic cystadenoma	10.5	KRT7, VEGFA, VHL
32	malignant teratocarcinosarcoma	10.5	MUC1, VIM
33	mucinous tubular and spindle renal cell carcinoma	10.5	KRT7, MME
34	acquired hemangioma	10.5	CA9, KRT7, VEGFA
35	cutaneous mucoepidermoid carcinoma	10.5	KRT7, MUC1
36	pagod syndrome	10.5	KRT7, MUC1
37	breast papillomatosis	10.5	MME, VIM
38	erythrocytosis, familial, 2	10.5	HIF1A, VHL
39	distal monosomy 9p	10.5	BIRC5, MUC1, VIM
40	hilar cholangiocellular carcinoma	10.5	HIF1A, MME, VEGFA, VHL
41	liver sarcoma	10.5	CA9, KRT7, MME
42	hepatorenal syndrome	10.4	KRT7, MME
43	renal cell carcinoma, papillary	10.4	CA9, KRT7, MME
44	benign multicystic peritoneal mesothelioma	10.4	KRT7, VIM
45	female breast upper-inner quadrant cancer	10.4	KRT7, MME
46	pyometritis	10.4	KRT7, MUC1, VEGFA
47	rectum mucinous adenocarcinoma	10.4	MUC1, VIM
48	breast ductal carcinoma	10.4	KRT7, MME
49	hartnup disorder	10.4	KRT7, MUC1, VEGFA
50	pancreatic invasive mucinous cystadenocarcinoma	10.4	KRT7, MME, MUC1

Graphical network of the top 20 diseases related to Renal Clear Cell Carcinoma:

Symptoms for Renal Clear Cell Carcinoma

Sources:
⁶⁵UMLS
See all MalaCards sources

UMLS symptoms related to Renal Clear Cell Carcinoma:

flank pain

Drugs & Therapeutics for Renal Clear Cell Carcinoma

Sources:
⁴⁴NIH Clinical Center, ⁴ClinicalTrials, ⁶⁵UMLS, ⁴³NDF-RT, ¹³DrugBank, ²⁶HMDB, ⁹DGIdb, ⁵³PharmGKB, ³⁰IUPHAR, ⁴⁷Novoseek, ¹BitterDB
See all MalaCards sources

Drugs for Renal Clear Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 276)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Sunitinib

approved, investigational

Phase 4, Phase 3, Phase 2, Phase 1

486

341031-54-7, 557795-19-4

5329102

Synonyms:

(2S)-2-hydroxybutanedioic acid

1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)

326914-13-0

341031-54-7

5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE

557795-19-4

AC1NS62J

AC1O5CMQ

AKOS005145765

Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)

CHEBI:38940

CHEBI:550864

CHEMBL1567

CHEMBL535

CID5329102

CID6456015

D06402

D08552

DB01268

DB07417

EN002687

FT-0083555

FT-0083556

I01-1229

K00588a

KS-5022

LS-186078

LS-187023

LS-187648

MolPort-003-986-763

N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate

N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

NCGC00164631-01

NSC736511

NSC750690

PDGF TK antagonist

PHA-290940AD

PNU-290940AD

S1042_Selleck

ST51053712

SU 011248

SU 11248

SU-010398

SU-011248 L-malate salt

SU-11248

SU-11248 L-malate salt

SU-11248J

SU-12662

SU010398

SU011248

SU011248 L-malate salt

SU11248

Su-011248

Sunitanib

Sunitinib

Sunitinib (INN)

Sunitinib (free base)

Sunitinib Malate

Sunitinib malate

Sunitinib malate (JAN/USAN)

Sunitinib malate [USAN]

Sunitinibum

Sutent

Sutent (TN)

Sutent, SU-11248

TL8002546

UNII-LVX8N1UT73

UNII-V99T50803M

sunitinib

sunitinibum

Nivolumab

approved

Phase 4, Phase 3, Phase 2, Phase 1

198

946414-94-4

Synonyms:

BMS-936558

MDX-1106

ONO-4538

nivolumab

Aldesleukin

approved

Phase 4, Phase 2, Phase 1, Phase 0

387

85898-30-2

Synonyms:

IL-2

Interleukin-2 precursor

Proleukin

T-cell growth factor

TCGF

Bevacizumab

approved, investigational

Phase 4, Phase 3, Phase 2, Phase 1

1875

216974-75-3

Synonyms:

216974-75-3

Avastin

Avastin (TN)

Bevacizumab

Bevacizumab (genetical recombination)

Bevacizumab (genetical recombination) (JAN)

D06409

R-435

anti-VEGF monoclonal antibody

antiVEGF

bevacizumab

Axitinib

approved, investigational

Phase 4, Phase 3, Phase 2, Phase 1

100

319460-85-0

6450551

Synonyms:

319460-85-0

790713-39-2

AC-1539

AC1O51X3

AG 013736

AG-013736

AG-013736, Axitinib

AG-13736

AG013736

Axitinib

C503983

CID6450551

EC-000.2322

I14-1971

INLYTA

Inlyta

MolPort-006-392-413

N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide

N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide

S1005_Selleck

SID103905539

ST51054130

UNII-C9LVQ0YUXG

ZINC03816287

axitinib

Angiogenesis Inhibitors

Phase 4, Phase 3, Phase 2, Phase 1

3688

Analgesics

Phase 4, Phase 3, Phase 2, Phase 1, Phase 0

9358

Protein Kinase Inhibitors

Phase 4, Phase 3, Phase 2, Phase 1, Phase 0

3162

Analgesics, Non-Narcotic

Phase 4, Phase 2, Phase 1, Phase 0

5184

Angiogenesis Modulating Agents

Phase 4, Phase 3, Phase 2, Phase 1

3611

Peripheral Nervous System Agents

Phase 4, Phase 3, Phase 2, Phase 1, Phase 0

18510

Interleukin-2

Phase 4, Phase 2, Phase 1, Phase 0

487

Epoetin alfa

approved

Phase 3

626

113427-24-0

Synonyms:

Epogen

Erythropoietin precursor

Procrit

Epirubicin

approved

Phase 3, Phase 2

361

56420-45-2

41867

Synonyms:

(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside

(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside

(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione

(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione

10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione

4'-Epi-DXR

4'-Epiadriamycin

4'-Epidoxorubicin

4'-epi-DX

4'-epi-Doxorubicin

4'-epidoxorubicin

4-Epidoxorubicin

56390-09-1

56390-09-1 (hydrochloride)

56420-45-2

57918-25-9

AC1L26NP

AC1Q6JIV

BRN 1445813

C11230

C27H29NO11

CCRIS 2261

CHEBI:47898

CHEMBL417

CID41867

D07901

DB00445

Ellence

Epi-DX

Epi-Dx

Epiadriamycin

Epidoxorubicin

Epirubicin

Epirubicin (INN)

Epirubicin [INN:BAN]

Epirubicina

Epirubicina [INN-Spanish]

Epirubicina [Spanish]

Epirubicine

Epirubicine [French]

Epirubicine [INN-French]

Epirubicinum

Epirubicinum [INN-Latin]

Epirubicinum [Latin]

Farmorubicin (TN)

HSDB 6962

IMI 28

LS-187190

LS-93992

MLS000759412

NChemBio.2007.10-comp15

NSC 256942

NSC-256942

NSC256942

Pharmorubicin Pfs

Pidorubicin

Pidorubicina

Pidorubicina [INN-Spanish]

Pidorubicine

Pidorubicine [INN-French]

Pidorubicinum

Pidorubicinum [INN-Latin]

Ridorubicin

SMR000466308

Triferric doxorubicin

UNII-3Z8479ZZ5X

WP 697

Methylphenidate

approved, investigational

Phase 3

364

113-45-1

4158

Synonyms:

.alpha.-Phenyl-2-piperidineacetic acid methyl ester

113-45-1

2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester

2-Piperidineacetic acid, alpha-phenyl-, methyl ester

298-59-9 (hydrochloride)

4311/B Ciba

AC1L1HJM

C 4311

C07196

CHEBI:6887

CHEMBL796

CID4158

Calocain

Centedein

Centedrin

Centedrine

Centredin

Concerta

D-Methylphenidate HCl

D04999

DB00422

DB06701

DEA No. 1724

Daytrana

Daytrana (TN)

EINECS 204-028-6

Focalin

Focalin XR

HSDB 3126

L001307

LS-565

METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)

MPH

Meridil

Metadate

Metadate CD

Metadate ER

MethyPatch

Methyl (2-phenyl-2-(2-piperidyl)acetate)

Methyl alpha-phenyl-alpha-(2-piperidyl)acetate

Methyl alpha-phenyl-alpha-2-piperidinylacetate

Methyl phenidate

Methyl phenidyl acetate

Methyl phenidylacetate

Methylfenidan

Methylin

Methylin ER

Methylofenidan

Methylphen

Methylphenidan

Methylphenidate

Methylphenidate (USAN/INN)

Methylphenidate HCl

Methylphenidate Hydrochloride

Methylphenidate [INN:BAN]

Methylphenidate hydrochloride

Methylphenidatum

Methylphenidatum [INN-Latin]

Methylphenidylacetate hydrochloride

Methypatch

Metilfenidat hydrochloride

Metilfenidato

Metilfenidato [INN-Spanish]

Metilfenidato [Italian]

MolPort-001-779-620

NCI-C56280

PMS-Methylphenidate

Phenidylate

Plimasine

Quillivant XR

Riphenidate

Ritalin

Ritalin LA

Ritalin SR

Ritalin hydrochloride

Ritalin-SR

Ritaline

Ritcher Works

Ritcher works

Tsentedrin

UNII-207ZZ9QZ49

alpha-Phenyl-2-piperidineacetic acid methyl ester

alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester

d-methylphenidate HCl

methyl 2-phenyl-2-piperidin-2-ylacetate

methyl phenyl(piperidin-2-yl)acetate

methylphenidate

nchembio.2007.55-comp28

Cisplatin

approved

Phase 3, Phase 2, Phase 1

2540

15663-27-1

84093, 441203, 2767

Synonyms:

(SP-4-1)-diamminedichloridoplatinum

(SP-4-1)-diamminedichloroplatinum

(SP-4-2)-diamminedichloridoplatinum

(SP-4-2)-diamminedichloroplatinum

Abiplatin

Biocisplatinum

Briplatin

CACP

CDDP

CHEBI:35852

CID441203

CPD0-1392

CPDC

CPDD

Carboquone

Cis Pt II

Cis-DDP

Cis-Diaminedichloroplatinum

Cis-Diamminedichloroplatinum

Cismaplat

Cisplatin

Cisplatine

Cisplatino

Cisplatinum

Cisplatyl

Citoplationo

DB00515

DDP

DDPT

Diamminedichloroplatinum

EU-0100918

Lederplatin

Neoplatin

Peyrone's chloride

Peyrone's salt

Plastin

Platamine

Platiblastin

Platidiam

Platinex

Platinol

Platinol-AQ

Platinol-aq

Platinoxan

Platinum Ammine Chloride

Platinum Ammonium Chloride

Platinum Diamine Dichloride

Randa

Trans-DDP

Trans-Diaminedichloroplatinum

Trans-Diamminedichloroplatinum

Trans-Dichlorodiammine Platinum

Trans-Platinumdiammine Dichloride

cis-DDP

cis-Diamminedichloroplatinum

cis-Dichlorodiammineplatinum(II)

cis-[PtCl2(NH3)2]

cis-diamminedichloridoplatinum(II)

cis-diamminedichloroplatinum(II)

nchembio773-comp1

trans-diamminedichloridoplatinum(II)

Octreotide

approved, investigational

Phase 2, Phase 3

198

83150-76-9

383414, 6400441

Synonyms:

(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa

10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

79517-01-4 (acetate salt)

83150-76-9

AC1L1GVU

AC1L8LCD

AC1L9M4X

C07306

C5H12O2.C4H10

CHEBI:427278

CHEBI:611465

CHEMBL1680

CID383414

CID448601

CID54374

D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide

D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide

D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide

D00442

DRG-0115

HMS2090C09

HS-2020

L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*

L000453

LS-177735

LS-187135

Longastatin

NCGC00181796-01

NCI60_025753

Ocphyl

Octreotida

Octreotida [Spanish]

Octreotide

Octreotide (USAN/INN)

Octreotide Acetate

Octreotide Acetate Salt

Octreotide [USAN:INN:BAN]

Octreotide acetate

Octreotide-LAR

Octreotidum

Octreotidum [Latin]

Octrotide

SAN 201-995

SM 201-995

SMS 201-995

SMS-201-995

Sandostatin

Sandostatine

Sandoz 201-995

UNII-RWM8CCW8GP

nchembio.184-comp3

zacycloicosane-4-carboxamide acetate

Morphine

approved, investigational

Phase 3

855

57-27-2

5288826

Synonyms:

(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol

(-)-Heroin hydrochloride

(-)-Morphine

(-)Morphine sulfate

(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol

(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol

(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol

(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol

(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol

(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL

(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol

(−)-morphine

17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol

4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol

4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol

47106-99-0

57-27-2

6211-15-0 (sulfate (2:1) (salt) pentahydrate)

64-31-3

64-31-3 (sulfate (2:1) (salt) anhydrous)

7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol

7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol

8053-16-5

85201-37-2

Apokyn

Astramorph PF

Avinza

BIDD:GT0147

C01516

CCRIS 5762

CHEBI:17303

CHEMBL70

CID5288826

Cube juice

D-(-)-Morphine

DB00295

DEA No. 9300

DepoDur

Depodur

Diacetylmorphine hydrochloride

Diamorphine hydrochloride

Dolcontin

Dreamer

Dulcontin

Duramorph

Duramorph PF

Duromorph

EINECS 200-320-2

Epimorph

HSDB 2134

Hard stuff

Heroin hydrochloride

Heroine hydrochloride

Hocus

Infumorph

Kadian

LS-91748

M-Eslon

M.O.S

MOI

MORPHINE SULFATE

MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE

MS Contin

MS/L

MS/S

MSIR

Meconium

MolPort-003-849-273

Morfina

Morfina [Italian]

Morphia

Morphin

Morphin [German]

Morphina

Morphina [Italian]

Morphine

Morphine Extra-Forte

Morphine Forte

Morphine H.P

Morphine Sulfate

Morphine [BAN]

Morphinism

Morphinum

Morphitec

Morphium

Morpho

Moscontin

Ms Contin

Ms Emma

NSC11441

Nepenthe

O,O'-Diacetylmorphine hydrochloride

OMS Concentrate

Oramorph SR

Ospalivina

RMS

RMS Uniserts

Rescudose

Roxanol

Roxanol 100

Roxanol UD

SDZ 202-250

SDZ202-250

Statex

Statex Drops

Statex SR

UNII-76I7G6D29C

Unkie

l-Morphine

morphine

nchembio.317-comp1

nchembio.64-comp1

Doxorubicin

approved, investigational

Phase 3, Phase 2, Phase 1

1582

23214-92-8

31703

Synonyms:

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside

(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

111266-55-8

14-Hydroxydaunomycin

14-Hydroxydaunorubicine

14-hydroxydaunomycin

14-hydroxydaunorubicine

23214-92-8

23257-17-2

24385-08-8

25311-50-6

25316-40-9

25316-40-9 (hydrochloride)

29042-30-6

AC1L1M5T

AC1Q29OJ

ADM

ADR

Adriablastin

Adriacin (hydrochloride salt)

Adriamycin

Adriamycin PFS

Adriamycin PFS (hydrochloride salt)

Adriamycin RDF

Adriamycin RDF (hydrochloride salt)

Adriamycin Semiquinone

Adriamycin semiquinone

Adriblas tina

Adriblastin

Adriblastina

Adriblastina (TN)

Adriblastina (hydrochloride salt)

Aerosolized Doxorubicin

BPBio1_000502

BRD-K92093830-003-04-3

BSPBio_000456

BSPBio_001031

C01661

C27H29NO11

CCRIS 739

CHEBI:28748

CHEMBL179

CID31703

Caelyx

Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74

Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120

D03899

DB00997

DM2

DOX-SL

Doxil

Doxo

Doxorubicin

Doxorubicin (USAN/INN)

Doxorubicin HCl

Doxorubicin Hydrochloride

Doxorubicin [USAN:INN:BAN]

Doxorubicin citrate

Doxorubicin hydrochloride (hydrochloride salt)

Doxorubicin-P4/D10

Doxorubicin-P4/D10 conjugate

Doxorubicin-hLL1

Doxorubicin-hLL1 conjugate

Doxorubicina

Doxorubicina [INN-Spanish]

Doxorubicine

Doxorubicine [INN-French]

Doxorubicinum

Doxorubicinum [INN-Latin]

EINECS 245-495-6

FI 106

Farmablastina (hydrochloride salt)

HMS2089H06

HSDB 3070

Hydroxydaunomycin hydrochlor ide (hydrochloride salt)

Hydroxydaunomycin hydrochloride (hydrochloride salt)

Hydroxydaunorubicin

Hydroxydaunorubicin hydrochloride (hydrochloride salt)

JT9100000

LMPK13050001

LS-1029

LS-165655

MLS000759533

Myocet

NCI-C01514

NChemBio.2007.10-comp13

NDC 38242-874

NIOSH/JT9100000

NSC 123127

Prestwick0_000438

Prestwick1_000438

Prestwick2_000438

Prestwick3_000438

Probes1_000151

Probes2_000129

RDF Rubex

Resmycin

Rubex

Rubex (hydrochloride salt)

SMP1_000106

SPBio_002395

TLC D-99

ThermoDox

Triferric doxorubicin

UNII-80168379AG

adiblastine (hydrochloride salt)

adr iablatina (hydrochloride salt)

adriablastine (hydrochloride salt)

adriablatina (hydrochloride salt)

adriblatina (hydrochloride salt)

doxorubicin

nchembio809-comp5

Dactinomycin

approved

Phase 3, Phase 2

50-76-0

2019, 457193

Synonyms:

(- )-actinomycin d

(-)-actinomycin d

-pentone

01815_FLUKA

1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine

2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-I)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide

4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide

50-76-0

A1410_SIGMA

A4262_SIGMA

A9415_SIGMA

AC1L1CQX

AC1L9W52

ACT

ACT D

ACTINOMYCIN D

ACTINOMYCIN D AMP

ACTINOMYCIN-D

ACTO-D

ACon0_000471

ACon1_001004

AD (VAN)

AI3-26374

ActD

Actactinomycin A IV

Actactinomycin a Iv

Actinomycin 11 Cosmegen

Actinomycin 11 cosmegen

Actinomycin 7

Actinomycin A IV

Actinomycin Aiv

Actinomycin C (sub1)

Actinomycin C(sub1)

Actinomycin C1

Actinomycin D

Actinomycin D (JP15)

Actinomycin D deriv. of 3H-phenoxaocardazine

Actinomycin D, sodium deoxyribonucleic acid complex

Actinomycin I

Actinomycin I (sub1)

Actinomycin I(sub 1)

Actinomycin I(sub1)

Actinomycin I1

Actinomycin IV

Actinomycin Iv

Actinomycin X 1

Actinomycin X1

Actinomycin iv

Actinomycin-(threo-val-pro-sar-meval)

Actinomycin-?IV

Actinomycin-[threo-val-pro-sar-meval]

Actinomycindioic D Acid, Dilactone

Actinomycindioic D acid, dilactone

Acto-D

Antibiotic From Streptomyces Parvullus

Antibiotic from Streptomyces parvullus

BCBcMAP01_000155

BRD-A42383464-001-02-2

Bio1_000342

Bio1_000831

Bio1_001320

C06770

C62H86N12O16

CBiol_002056

CCRIS 9

CHEBI:123721

CHEBI:27666

CHEMBL1554

CHEMBL427947

CID2019

CID457193

COSMEGEN (TN)

CPD000469227

Chounghwamycin B

Cosmegen

D Actinomycin

D00214

DACTINOMYCIN

DB00970

DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA

Dactinomicina

Dactinomicina [INN-Spanish]

Dactinomycin

Dactinomycin (USP)

Dactinomycin D

Dactinomycin [USAN:BAN]

Dactinomycine

Dactinomycine [INN-French]

Dactinomycinum

Dactinomycinum [INN-Latin]

Dilactone Actinomycin D Acid

Dilactone Actinomycindioic D Acid

Dilactone actin omycindioic D acid

Dilactone actinomycin D acid

Dilactone actinomycindioic D acid

EINECS 200-063-6

FT-0080366

GNF-PF-1977

HBF 386

HBF 386 Meractinomycin

HBF 386 meractinomycin

HMS2052O17

HSDB 3220

LMPK14000005

LS-142

Lyovac Cosmegen

Lyovac cosmegen

MEGxm0_000350

MLS001424196

Meractinomycin

MolPort-001-739-741

MolPort-003-925-177

NCGC00025059-02

NCGC00090796-01

NCGC00161622-01

NCGC00161622-02

NCGC00169767-01

NCI-C04682

NCI60_030539

NP-005932

NSC 3053

NSC-3053

NSC191297

NSC3053

Neuro_000003

Oncostatin K

Oxamide

PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA

SAM001246846

SMP1_000005

SMR000469227

UNII-1CC1JFE158

UPCMLD-DP055

UPCMLD-DP055:001

UPCMLD-DP055:002

WLN: 16- AN FVN IVN LVO PVM SVTJ G1 J1 KY1&1 N1 RY1&1

X 97

actd

actinomycin D

actinomycin cl

actinomycin x i

actinomyein-theo-val-pro-sar-meval

dactinomyein d

o)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine

Fentanyl

approved, illicit, investigational

Phase 3

705

437-38-7

3345

Synonyms:

1-Phenethyl-4-(N-phenylpropionamido)piperidine

1-Phenethyl-4-N-propionylanilinopiperidine

437-38-7

5-22-08-00049 (Beilstein Handbook Reference)

80832-90-2

990-73-8 (citrate)

AC1L1FQ2

Abstral

Actiq

BIDD:GT0555

BRN 0494484

CHEBI:119915

CHEMBL596

CID3345

D00320

DB00813

Duragesic

Duragesic (TN)

Duragesic-100

Duragesic-12

Duragesic-25

Duragesic-50

Duragesic-75

Durogesic

EINECS 207-113-6

Fentanest

Fentanil

Fentanil [DCIT]

Fentanila

Fentanila [INN-Spanish]

Fentanilo

Fentanyl

Fentanyl (JAN/USAN/INN)

Fentanyl - Novaplus

Fentanyl Citrate

Fentanyl [INN:BAN]

Fentanyl citrate

Fentanyl-100

Fentanyl-12

Fentanyl-25

Fentanyl-50

Fentanyl-75

Fentanylum

Fentanylum [INN-Latin]

HSDB 3329

IONSYS

JNS020QD

L001275

LS-124439

Lazanda

Matrifen

MolPort-003-847-369

N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide

N-(1-Phenethyl-4-piperidyl)propionanilide

N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide

N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide

N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide

N-Phenethyl-4-(N-propionylanilino)piperidine

N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide

N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide

NCGC00168252-01

Nasalfent

Oprea1_152073

Oprea1_207148

PDSP1_000860

PDSP2_000846

Pentanyl

Phentanyl

Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)

R 4263

Rapinyl

Sentonil

Sublimase

Sublimaze

Subsys

UNII-UF599785JZ

fentanyl

Gemcitabine

approved

Phase 3, Phase 2

1881

95058-81-4

60750

Synonyms:

103882-84-4

122111-03-9

2',2'-DiF-dC

2',2'-Difluoro-2'-deoxycytidine

2',2'-Difluorodeoxycytidine

2'-Deoxy-.beta.-D-2',2'-difluorocytidine

2'-Deoxy-2',2'-difluorocytidine

4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one

4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one

4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

95058-81-4

AB1004842

AC1L1TUQ

C07650

CCRIS 8984

CHEBI:175901

CHEMBL888

CID60750

Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine

D02368

DB00441

DDFC

DFDC

DFdC

DFdCyd

Folfugem

GEO

Gamcitabine

GemLip

Gemcel

Gemcin

Gemcitabin

Gemcitabina

Gemcitabina [INN-Spanish]

Gemcitabine

Gemcitabine (USAN/INN)

Gemcitabine HCl

Gemcitabine Hydrochloride

Gemcitabine hydrochloride

Gemcitabine stereoisomer

Gemcitabinum

Gemcitabinum [INN-Latin]

Gemtro

Gemzar

Gemzar (hydrochloride)

HMS2089P10

HSDB 7567

Inno-D07001

LS-59139

LY 188011

LY-188011

LY188011

NCGC00168784-01

NChemBio.2007.10-comp25

NSC 613327

NSC613327

TL8005979

UNII-B76N6SBZ8R

ZINC18279854

Zefei

gemcitabine

nchembio.573-comp7

nchembio.90-comp2

Etoposide

approved

Phase 3, Phase 2, Phase 1

1169

33419-42-0

36462

Synonyms:

(-)-Etoposide

121471-01-0

136598-18-0

201594-04-9

33419-42-0

35317-32-9

4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside

4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)

4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)

4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside

4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin

4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside

4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside

51854-34-3

76576-58-4

9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one

AB00438905

AC1L1FN8

AC1L1VT3

AC1L6246

AC1NR4OG

AC1O4WGG

AC1O7M1N

AC1Q47JJ

Ambap33419-42-0

BPBio1_000673

BRD-K37798499-001-02-5

BSPBio_000611

Bio1_000489

Bio1_000978

Bio1_001467

C01576

CCRIS 2392

CHEBI:4911

CHEBI:588795

CHEMBL44657

CID11758093

CID284997

CID3310

CID36462

CID5284558

CID6419930

CID6610299

CPD000112002

D00125

DB00773

DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,

Demethyl Epipodophyllotoxin Ethylidine Glucoside

Demethyl-epiodophyllotoxin ethylidene glucoside

Demethylepipodophyllotoxin-beta-D-ethylideneglucoside

E0675

E1383_SIGMA

EINECS 251-509-1

EPE

EPEG

ETOP

Epipodophyllotoxin

Epipodophyllotoxin VP-16213

Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside

Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside

Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)

Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)

Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)

Eposide

Eposin

Eposin, Vepesid, VP-16, Toposar, Etoposide

Etopol

Etopophos

Etopophos (phosphate salt)

Etoposid

Etoposide

Etoposide (JP15/USP/INN)

Etoposide (VP16)

Etoposide Phosphate

Etoposide [USAN:INN:BAN:JAN]

Etoposido

Etoposido [INN-Spanish]

Etoposidum

Etoposidum [INN-Latin]

Etosid

HMS1569O13

HMS2052N05

HMS2089F14

HSDB 6517

I06-0248

KBioSS_002410

LS-1214

Lastet

MLS000049957

MLS001074951

MLS001424283

MLS002153463

MLS002207239

MLS002222184

MolPort-003-983-431

MolPort-004-905-001

MolPort-004-955-161

NCGC00025056-02

NChemBio.2007.10-comp19

NK 171

NSC 141540

NSC-141540

NSC141540

Prestwick0_000396

Prestwick1_000396

Prestwick2_000396

Prestwick3_000396

Prestwick_211

S1225_Selleck

SAM001246880

SMR000112002

SPBio_002532

ST056353

Toposar

UNII-6PLQ3CP4P3

VP 16

VP 16 (pharmaceutical)

VP 16-213

VP 16213

VP-16

VP-16-213

VePESID (TN)

VePesid

Vepesid

Vepesid J

Vepeside

ZINC03830818

ZINC03938684

Zuyeyidal

etoposide

nchembio.573-comp8

nchembio873-comp2

trans-Etoposide

Vincristine

approved, investigational

Phase 3, Phase 2

863

2068-78-2, 57-22-7

5978

Synonyms:

22-Oxovincaleukoblastin

22-Oxovincaleukoblastine

28379-27-3

57-22-7

AC1L1LJC

C07204

C46H56N4O10

CCRIS 5763

CHEBI:28445

CID5978

D08679

DB00541

EINECS 200-318-1

HMS2090E19

HSDB 3199

Indole alkaloid

LCR

LS-228

Leurocristine

Lilly 37231 (1:1 sulfate salt)

Liposomal Vincristine

Marqibo

NCGC00163700-01

NCI-C04864

NCI60_026703

NSC-67574

Onco TCS

Oncovin

Oncovin (1:1 sulfate salt)

Oncovine

Tecnocris

Tecnocris (TN)

UNII-5J49Q6B70F

VCR

VIN

Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine

Vincasar

Vincasar (1:1 sulfate salt)

Vincasar PFS

Vincrex

Vincrex (1:1 sulfate salt)

Vincristin

Vincristina

Vincristina [DCIT]

Vincristine (INN)

Vincristine Sulfate

Vincristine Sulfate PFS

Vincristine [INN:BAN]

Vincristinum

Vincristinum [INN-Latin]

Vincrstine

Vincrystine

Vinkristin

Z-D-Val-Lys(Z)-OH

vincristine

Capecitabine

approved, investigational

Phase 3, Phase 2

1220

154361-50-9

60953

Synonyms:

(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester

154361-50-9

158798-73-3

5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine

5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine

AC1L1U83

AC1Q4KU8

Ambap154361-50-9

C110904

C12650

C15H22FN3O6

CAPE

CAPECITABINE

CHEBI:31348

CHEMBL1773

CID60953

Capecitabin

Capecitabina

Capecitabine

Capecitabine (JAN/USAN/INN)

Capecitabine [USAN]

Capecitabinum

Capecitibine

Capiibine

Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester

Caxeta

D01223

DB01101

FT-0082472

HSDB 7656

LS-59070

MolPort-005-938-254

N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine

Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate

Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate

R-340

R340

RG-340

Ro 09-1978

Ro 09-1978/000

Ro-09-1978

Ro-09-1978/000

S1156_Selleck

UNII-6804DJ8Z9U

Xabine

Xeloda

Xeloda (TN)

Xeloda, Captabin, Capecitabine

ZINC03806413

capecitabina

capecitabine

capecitabinum

pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate

Sorafenib

approved, investigational

Phase 3, Phase 2, Phase 1

671

284461-73-0

216239, 406563

Synonyms:

284461-73-0

4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide

4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide

4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate

4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide

4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide

4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide

4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide

4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide

4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE

AB1004622

AC-1674

AC1L50CF

BAX

BAY 43-9006

BAY 43-9006 (free base)

BAY 43-9006 tosylate salt

BAY 439006

BAY 54-9085 (tosylate salt)

BAY-43-0006

BAY-43-9006

BAY-54-9085

BAY43-9006

BRD-K23984367-001-01-8

Bio-0100

CHEBI:47228

CHEBI:50924

CHEMBL1336

CID216239

D08524

DB00398

DB07438

EN002709

I06-0856

K00597a

Kinome_766

LS-186067

LS-187021

LS-187788

MolPort-003-850-270

N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea

N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea

N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea

N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea

NCGC00167488-01

NSC-724772

NSC747971

Nexavar

STK627350

Sorafenib

Sorafenib (INN)

Sorafenib Tosylate

Sorafenib [INN]

Sorafenib tosylate

Sorafenibum

UNII-9ZOQ3TZI87

ZINC01493878

nchembio.117-comp17

sorafenib

sorafenibum

Oxaliplatin

approved, investigational

Phase 3, Phase 2

1322

61825-94-3

5310940, 9887054, 6857599, 43805, 6857599, 9887054

Synonyms:

CHEMBL1201055

CID9887054

D01790

DACPLAT

Diaminocyclohexane Oxalatoplatinum

Eloxatin

Eloxatin (TN)

Elplat

Foloxatine

L-OHP

Oxalatoplatin

Oxalatoplatinum

Oxaliplatin

Oxaliplatin (JAN/USAN/INN)

Oxaliplatin [Usan:Inn:Ban]

Oxaliplatino [Spanish]

Oxaliplatinum [Latin]

Oxaloplatine [French]

Oxaloplatino [Spanish]

Transplatin

oxaliplatin

Sirolimus

approved, investigational

Phase 3, Phase 2, Phase 1

1797

53123-88-9

5284616, 6436030, 46835353

Synonyms:

(-)-Rapamycin

(-)-rapamycin

1fkb

1pbk

23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine

23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine

23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29

3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

53123-88-9

A422989, NSC226080

AC-722

AC1L1JH9

AC1L7MJ9

AC1L9ZMV

AY 22989

AY-22989

AY22989

Ambotz53123-88-9

Antibiotic AY 22989

BIDD:PXR0165

Bio1_000293

Bio1_000782

Bio1_001271

Bio2_000375

Bio2_000855

BiomolKI2_000084

C07909

C51H79NO13

CBiol_002007

CCRIS 9024

CHEBI:100923

CHEBI:9168

CHEMBL413

CID10213190

CID10795871

CID11949238

CID11959112

CID313006

CID478951

CID5040

CID5284616

CID5358081

CID5374464

CID5460439

CID5497196

CID5924240

CID6436030

CID6610270

CID6610346

CID6711160

CID6713081

CID9833581

CID9854379

CID9854380

CID9962926

CID9962928

D00753

DB00877

DE-109

DivK1c_006936

FT-0082351

HMS2089A21

HSDB 7284

KBio1_001880

KBio2_000410

KBio2_002978

KBio2_005546

KBio3_000779

KBio3_000780

KBioGR_000410

KBioSS_000410

LCP-Siro

LMPK06000003

LS-143290

MLS000028373

MS-R001

MolMap_000043

MolPort-003-959-433

NCGC00021305-05

NCI60_001851

NCIMech_000355

NSC 226080

NSC226080

Perceiva

QTL1_000069

R0395_SIAL

R0395_SIGMA

RAP

RAPA

RPM

Rapammune

Rapamune

Rapamune (TN)

Rapamycin

Rapamycin (TN)

Rapamycin C-7, analog 4

Rapamycin Immunosuppressant Drug

Rapamycin from Streptomyces hygroscopicus

S1039_Selleck

SIIA 9268A

SILA 9268A

SILA9268A

SMP1_000255

SMR000058564

Sirolimus

Sirolimus (RAPAMUNE)

Sirolimus (USAN/INN)

Sirolimus [USAN:BAN:INN]

Sirolimus, Rapamune,Rapamycin

SpecPlus_000840

UNII-W36ZG6FT64

UNM-0000358684

WY-090217

Wy 090217

heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy

nchembio.100-comp4

nchembio.2007.42-comp2

nchembio.79-comp1

nchembio762-comp1

nchembio883-comp3

rapamycin

sirolimus

Miconazole

approved, investigational

Phase 3, Phase 2, Phase 1

3026

22916-47-8

4189

Synonyms:

(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole

1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole

1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole

1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole

1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole

1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole

1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole

1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole

1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole

1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole

22832-87-7 (NITRATE)

22916-47-8

75319-47-0

AB00053500

AC1L1HM1

AKOS001574474

Aflorix(nitrate)

Albistat(nitrate)

Andergin(nitrate)

BPBio1_000279

BRD-A82396632-001-03-0

BRD-A82396632-008-02-7

BRN 0965511

BSPBio_000253

BSPBio_002033

CCRIS 7924

CHEBI:6923

CHEMBL91

CID4189

CPD-4501

Conofite(nitrate)

D00416

DB01110

Dactarin

Daktarin IV

Daktarin iv

Desenex

DivK1c_000156

EINECS 245-324-5

Epi-Monistat(nitrate)

Femizol-M

Florid(nitrate)

Gyno-Daktar(nitrate)

HMS1568M15

HMS2090B21

I14-14342

IDI1_000156

Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)

KBio1_000156

KBio2_001445

KBio2_004013

KBio2_006581

KBio3_001533

KBioGR_000581

KBioSS_001445

LS-78378

Lotrimin AF(nitrate)

MCZ

MJR 1762

MLS002222203

Makesense

Micantin (nitrate)

Micatin

Miconasil Nitrate

Miconazol

Miconazol [INN-Spanish]

Miconazole

Miconazole (JP15/USP/INN)

Miconazole 3

Miconazole 3 Combination Pack

Miconazole 7 Combination Pack

Miconazole [USAN:BAN:INN:JAN]

Miconazole nitrate salt

Miconazole-7

Miconazolo

Miconazolo [DCIT]

Miconazolum

Miconazolum [INN-Latin]

Micozole

Minostate

MolPort-002-557-553

Monazole 7

Monista (nitrate)

Monistat

Monistat (TN)

Monistat 1 Combination Pack

Monistat 3 Dual-Pak

Monistat 3 Vaginal Ovules

Monistat 5 Tampon

Monistat 7 Dual-Pak

Monistat 7 Vaginal Suppositories

Monistat Dual- PAK

Monistat IV

Monistat iv (TN)

Monistat iv (tn)

Monistat-Derm

NCI60_001353

NCI60_001380

NINDS_000156

NSC 170986

NSC169434

NSC170986

Novo-Miconazole Vaginal Ovules

Oprea1_091955

Oravig

Prestwick0_000067

Prestwick1_000067

Prestwick2_000067

Prestwick3_000067

Prestwick_335

R 18134

R-14,889

Rash Relief Antifungal

SMR001307249

SPBio_000976

SPBio_002174

STK834405

STOCK1S-93556

Spectrum2_001048

Spectrum3_000507

Spectrum4_000061

Spectrum5_001297

Spectrum_000965

UNII-7NNO0D7S5M

Vusion

Zimycan

imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)

miconazole

Pancrelipase

approved

Phase 2, Phase 3, Phase 1

880

53608-75-6

Synonyms:

1,4-alpha-D- glucan glucanohydrolase

Creon

Pancreatic alpha-amylase precursor

Pancreaze

Pancrelipase

Pertzye

Polocaine-mpf

Ultresa

Viokace

Zenpep

Carboplatin

approved

Phase 3, Phase 2, Phase 1

1885

41575-94-4

10339178, 498142, 38904

Synonyms:

(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum

/h1-3H2,(H,7,8)(H,9,10)

1,1-Cyclobutanedicarboxylate diammine platinum (II)

1,1-Cyclobutanedicarboxylate diammine platinum(II)

2*-1

2*1H2

41575-94-4

70903-55-8

AC-1457

AC1L8I6U

Ambap41575-94-4

BSPBio_003145

C 2538

C2043

C2538_SIGMA

C6H10N2O4Pt

CBDCA

CCRIS 3404

CHEBI:31355

CHEMBL1351

CHEMBL288376

CID10339178

CID2567

CID38904

CID426756

CID498142

CID5352133

CID6398587

CID6603770

Carbopaltin

Carboplatin

Carboplatin (JAN/USP/INN)

Carboplatin (USAN)

Carboplatin [USAN:INN:BAN:JAN]

Carboplatine

Carboplatine [French]

Carboplatino

Carboplatino [Spanish]

Carboplatinum

Carboplatinum [Latin]

Cbdca

Cyclobutane-1,1-dicarboxylate

D01363

DB00958

Diammine(1,1-cyclobutanedicarboxylato)platinum (II)

Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum

Diammine-1,1-cyclobutane dicarboxylate platinum II

DivK1c_000892

EINECS 255-446-0

EU-0100230

Ercar

HMS1921J16

HMS2090M05

HMS2092B22

HMS502M14

HSDB 6957

I14-2390

IDI1_000892

IUPAC: Azane

InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6

JM 8

JM-8

KBio1_000892

KBio2_002009

KBio2_004577

KBio2_007145

KBio3_002645

KBioGR_000713

KBioSS_002009

LS-117689

Lopac-C-2538

Lopac0_000230

MolPort-003-665-501

MolPort-003-845-609

NCGC00015223-01

NCGC00093695-01

NCGC00094961-01

NCGC00094961-02

NCGC00094961-03

NCGC00162099-01

NCGC00162099-02

NCGC00167800-01

NCGC00178242-01

NINDS_000892

NSC 201345

NSC 241240

NSC-241240

NSC201345

NSC241240

Paraplatin

Paraplatin (TN)

Paraplatin, Carboplatin

Paraplatin-AQ

Platinum(+2) Cation

Platinum(II), (1, 1-cyclobutanedicar

Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)

Platinum, {diammine[1,1-cyclobut

S1215_Selleck

SPBio_000716

SPECTRUM1502106

Spectrum2_000898

Spectrum3_001503

Spectrum4_000337

Spectrum5_001094

Spectrum_001529

UNII-BG3F62OND5

azanide

carboplatin

cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)

cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)

cis-Diammine(1,1-cyclobutanedicarboxylato) platinum

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diammine(cyclobutanedicarboxylato)platinum II

cyclobutane-1,1-dicarboxylic acid

diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum

nchembio.573-comp10

nchembio773-comp2

nchembio873-comp3

platinum(2+)

Everolimus

approved

Phase 3, Phase 2, Phase 1

1797

159351-69-6

6442177

Synonyms:

(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone

(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone

(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont

(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy

07741_FLUKA

159351-69-6

40-O-(2-hydroxyethyl)-rapamycin

42-O-(2-Hydroxyethyl)rapamycin

Afinitor

Afinitor Disperz

CERTICAN(R)

CHEMBL1201755

Certican

D02714

DB01590

Everolimus

Everolimus (JAN/USAN/INN)

Everolimus [USAN]

LS-143292

MolPort-003-847-342

MolPort-003-925-588

NCGC00167512-01

NVP-RAD-001

RAD 001

RAD-001

RAD-001C

RAD001

RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus

S1120_Selleck

SDZ-RAD

UNII-9HW64Q8G6G

VOTUBIA

Zortress

everolimus

Cyclophosphamide

approved, investigational

Phase 3, Phase 2, Phase 1

2643

50-18-0, 6055-19-2

2907

Synonyms:

(+-)-Cyclophosphamide

(-)-Cyclophosphamide

(RS)-Cyclophosphamide

1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine

1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin

2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide

4-Hydroxy-cyclophosphan-mamophosphatide

50-18-0

60007-95-6

6055-19-2 (monohydrate)

75526-90-8

AC1L1EQQ

AI3-26198

ASTA

ASTA B518

Asta B 518

B 518

B-518

BRN 0011744

BSPBio_002099

Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester

C 0768

C07888

C7H15Cl2N2O2P

CB 4564

CB-4564

CCRIS 188

CHEBI:4027

CHEMBL32520

CHEMBL88

CID2907

CPA

CTX

Ciclofosfamida

Ciclofosfamida [INN-Spanish]

Ciclofosfamide

Ciclophosphamide

Ciclophosphamide [INN]

Clafen

Claphene

Cycloblastin

Cyclophosphamid

Cyclophosphamide

Cyclophosphamide (INN)

Cyclophosphamide (TN)

Cyclophosphamide (anhydrous form)

Cyclophosphamide (anhydrous)

Cyclophosphamide Monohydrate

Cyclophosphamide Sterile

Cyclophosphamide anhydrous

Cyclophosphamide, (+-)-Isomer

Cyclophosphamides

Cyclophosphamidum

Cyclophosphamidum [INN-Latin]

Cyclophosphan

Cyclophosphane

Cyclophosphanum

Cyclophosphoramide

Cyclostin

Cyklofosfamid

Cyklofosfamid [Czech]

Cytophosphan

Cytophosphane

Cytoxan

Cytoxan (TN)

Cytoxan Lyoph

D,L-Cyclophosphamide

D07760

DB00531

DivK1c_000246

EINECS 200-015-4

EU-0100238

Endoxan

Endoxan R

Endoxan-Asta

Endoxana

Endoxanal

Endoxane

Enduxan

Genoxal

HMS2090A12

HSDB 3047

Hexadrin

IDI1_000246

KBio1_000246

KBio2_001338

KBio2_003906

KBio2_006474

KBio3_001319

KBioGR_000888

KBioSS_001338

LS-1302

LS-99787

Ledoxina

Lopac-C-0768

Lopac0_000238

Lyophilized Cytoxan

Mitoxan

MolPort-001-783-420

N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide

N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

NCGC00015209-01

NCGC00015209-03

NCGC00015209-06

NCGC00091741-02

NCGC00091741-03

NCI-C04900

NCI60_002097

NINDS_000246

NSC 26271

NSC-26271

NSC26271

NSC273033

NSC273034

Neosar

Occupation, cyclophosphamide exposure

Procytox

RCRA waste no. U058

Rcra Waste Number U058

Rcra waste number U058

Revimmune

S1217_Selleck

SK 20501

SPBio_001071

STK177249

STOCK2S-91217

Semdoxan

Sendoxan

Senduxan

Spectrum2_001146

Spectrum3_000370

Spectrum4_000304

Spectrum5_000795

Spectrum_000858

UNII-6UXW23996M

WLN: T6MPOTJ BO BN2G2G

Zyklophosphamid

Zyklophosphamid [German]

bis(2-Chloroethyl)phosphami de cyclic propanolamide

bis(2-Chloroethyl)phosphamide cyclic propanolamide ester

cyclophosphamide

Paclitaxel

approved

Phase 3, Phase 2, Phase 1

2621

33069-62-4

36314

Synonyms:

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

157069-30-2

33069-62-4

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.

7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.

7-Epi-Paclitaxel

7-Epi-Taxol

7-Epipaclitaxel

7-Epitaxol

7-epi-Paclitaxel

7-epi-Taxol

AB00513812

ABI 007

ABI-007

ABI007

AC-675

AC1L1IOG

AC1L1VJI

AC1L9AVF

ACon1_002231

ANX-513

Abraxane

Abraxane (TN)

Abraxane I.V. Suspension

Abraxis BioScience brand of albumin-bound paclitaxel

Ambotz33069-62-4

Anzatax

Asotax

BIDD:PXR0046

BMS 181339-01

BMS-181339

BMS-181339-01

BPBio1_000320

BRD-A23723433-001-01-2

BRD-A28746609-001-04-0

BRD-K62008436-001-03-1

BSPBio_000290

BSPBio_001152

BSPBio_002614

Bio-0076

Bio1_000362

Bio1_000851

Bio1_001340

Bio2_000416

Bio2_000896

Bristaxol

C07394

C466458

C47H51NO14

CCRIS 8143

CHEBI:103439

CHEBI:45863

CHEMBL100910

CHEMBL418410

CHEMBL48

CID36314

CID441276

CID4666

CID6713921

CID6915727

CPD-8718

Capxol

D00491

DB01229

DHP-107

DHP-208

DRG-0190

DTS-301

DivK1c_000441

EU-0101201

Ebetaxel

EmPAC

Epitaxol

Genaxol

Genetaxyl

Genexol

Genexol-PM

HMS1362J13

HMS1568O12

HMS1792J13

HMS1922K08

HMS1990J13

HMS2090D07

HMS2093K15

HMS501G03

HSDB 6839

I06-0014

IDI1_000441

IDI1_002171

Intaxel

KBio1_000441

KBio2_000492

KBio2_002016

KBio2_002509

KBio2_003060

KBio2_004584

KBio2_005077

KBio2_005628

KBio2_007152

KBio2_007645

KBio3_000903

KBio3_000904

KBio3_001834

KBio3_002987

KBioGR_000492

KBioGR_001893

KBioGR_002509

KBioSS_000492

KBioSS_002016

KBioSS_002517

LMPR0104390001

LS-31070

LipoPac

Lopac0_001201

MBT 0206

MEGxp0_001940

MLS000863266

MLS001077297

MLS002154218

MLS002172439

MLS002695976

MPI-5018

Micellar Paclitaxel

Mitotax

MolPort-001-742-627

MolPort-003-665-783

MolPort-003-932-365

NCGC00024995-02

NCGC00024995-03

NCGC00024995-04

NCGC00024995-05

NCGC00024995-06

NCGC00024995-07

NCGC00164367-01

NCGC00164367-02

NCGC00164367-03

NCI60_000601

NINDS_000441

NK 105

NP-010981

NSC 125973

NSC-125973

NSC125973

NSC358882

Nanotaxel

Neuro_000060

Nova-12005

OAS-PAC-100

OncoGel

Onxal

Onxol

Onxol, Taxol, Nov-Onxol, Paclitaxel

P1632

Paclical

Pacligel

Paclitaxel

Paclitaxel (JAN/USP)

Paclitaxel (JAN/USP/INN)

Paclitaxel (Taxol)

Paclitaxel [USAN:INN:BAN]

Paxceed

Paxene

Paxoral

Plaxicel

Praxel

Prestwick0_000155

Prestwick1_000155

Prestwick2_000155

Prestwick3_000155

Probes2_000350

QW 8184

S-8184 Paclitaxel Injectable Emulsion

S1150_Selleck

SDCCGMLS-0066823.P001

SDP-013

SMP1_000228

SMR000394086

SMR000857385

SPBio_000943

SPBio_002229

SPECTRUM1503908

ST50306996

Spectrum2_000872

Spectrum3_001057

Spectrum4_001197

Spectrum5_001491

Spectrum_001536

T 7402

T1912_SIGMA

T7191_SIGMA

T7402_SIGMA

TA1

TAXOL (TN)

TAXOL, 10-EPI,

TXL

TaxAlbin

Taxol

Taxol A

Taxol Konzentrat

Taxol.RTM. (Registered Trademark)

UNII-P88XT4IS4D

UPCMLD-DP108:001

UPCMLD-DP108:002

Vascular Wrap

Xorane

Yewtaxan

abi-007

albumin-bound paclitaxel

cMAP_000068

nchembio.188-comp1

nchembio.2007.34-comp9

nchembio.215-comp9

nchembio853-comp6

paclitaxel

weekly paclitaxel

Topotecan

approved, investigational

Phase 2, Phase 3, Phase 1

330

119413-54-6

60700

Synonyms:

(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione

(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione

(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE

(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione

(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione

123948-87-8

9-Dimethylaminomethyl-10-hydroxycamptothecin

9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin

AC-11592

AC1L1TQZ

AC1Q6APZ

BSPBio_002348

C11158

C23H23N3O5

CCRIS 8163

CHEBI:107501

CHEBI:46035

CHEMBL84

CID60700

D08618

DB01030

HMS2090B20

HSCI1_000228

Hycamptamine

Hycamptin

Hycamtamine

Hycamtin

Hycamtin (TN)

LS-127395

MLS000759456

NCGC00178695-01

NCI60_004771

NCIStruc1_001659

NCIStruc2_001796

NChemBio.2007.10-comp24

NSC609699

SK&F-104864-A

SKF 104864

SKF-104864-A

SKF-S 104864

SMP2_000312

SMP2_000327

SMR000466344

TOPO

TOPOTECAN, HYCAMTIN

TPT

TTC

Topotecan

Topotecan (BAN)

Topotecan Hcl

Topotecan Hydrochloride

Topotecan Lactone

Topotecan Monohydrochloride, (S)-Isomer

Topotecan [INN:BAN]

Topotecan lactone

Topotecane

Topotecane [INN-French]

Topotecanum

Topotecanum [INN-Latin]

UNII-7M7YKX2N15

topotecan

Metformin

approved

Phase 2, Phase 3

1645

657-24-9, 1115-70-4

14219, 4091

Synonyms:

1,1-Dimethyl biguanide

1,1-Dimethylbiguanide

3-(diaminomethylidene)-1,1-dimethylguanidine

657-24-9

AC1L1HE4

AKOS000121065

Apo-Metformin

BIDD:GT0697

BPBio1_000009

BRD-K79602928-003-04-1

BSPBio_000007

BSPBio_002314

C07151

C4H11N5

CAS-1115-70-4

CCRIS 9321

CHEBI:6801

CHEMBL1431

CID4091

D04966

DB00331

DMBG

DMGG

Diabefagos

Diabetosan

Diabex

Diaformin

Dianben

Dimethylbiguanid

Dimethylbiguanide

Dimethylbiguanidine

Dimethyldiguanide

Dimethylguanylguanidine

EINECS 211-517-8

Fluamine

Flumamine

Fortamet

Gen-Metformin

Glifage

Gliguanid

Glucophage

Glucophage XR

Glumetza

Glycon

HMS2089D19

HSCI1_000295

Haurymelin

Haurymellin

Islotin

KBio2_002310

KBio2_004878

KBio2_007446

KBio3_002790

KBioGR_002310

KBioSS_002312

LA-6023

LS-43899

Meguan

Melbin

Metformin

Metformin (USAN/INN)

Metformin HCL

Metformin Hydrochloride

Metformin [USAN:INN:BAN]

Metformina

Metformina [DCIT]

Metformina [Spanish]

Metformine

Metformine [INN-French]

Metformine pamoate

Metforminum

Metforminum [INN-Latin]

Metiguanide

MolPort-002-929-560

MolPort-004-288-389

MolPort-005-767-418

Mylan-Metformin

N,N-Dimethylbiguanide

N,N-Dimethyldiguanide

N,N-Dimethylimidodicarbonimidic diamide

N,N-dimethylimidodicarbonimidic diamide

N1,N1-Dimethylbiguanide

NCGC00016564-01

NCGC00016564-02

NCGC00016564-03

NNDG

Novo-Metformin

Nu-Metformin

Obimet

PMS-Metformin

Prestwick0_000004

Prestwick1_000004

Prestwick2_000004

Prestwick3_000004

Ran-Metformin

Ratio-Metformin

Riomet

S2483_Selleck

SPBio_001928

STK011633

Sandoz Metformin

Siofor

T5895664

Teva-Metformin

UNII-9100L32L2N

ZINC12859773

cMAP_000016

metformin

metformin hydrochloride

Olaparib

approved

Phase 2, Phase 3

104

763113-22-0

23725625

Synonyms:

4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one

4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one

4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one

763113-22-0

937799-91-2

AKOS005145764

AZD 2281

AZD-2281

AZD2281

Acylpiperazine analogue, 47

CHEMBL521686

EC-000.2324

EN002690

FT-0083489

KU-0059436

KU-59436

Olaparib

Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281

S1060_Selleck

olaparib

Succinylcholine

approved

Phase 3, Phase 2, Phase 1

141

306-40-1

5314

Synonyms:

2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)

2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)

2ha2

2ha6

306-40-1

4-04-00-01451 (Beilstein Handbook Reference)

541-19-5 (diiodide)

55-94-7 (dibromide)

71-27-2 (dichloride)

AC1L1K2T

Anectine

BRN 1805311

C07546

C14H30N2O4

CHEBI:45652

CHEMBL703

CID5314

Choline, succinate (2:1) (ester)

Choline, succinate (ester)

DB00202

Diacetylcholine

Dicholine succinate

Ditilin

Ditiline

HMS2090P14

HSDB 3254

InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2

L000926

LS-53328

Listenon

Lopac-S-8251

Lopac0_001080

Lysthenon

MolPort-002-964-486

NCGC00015971-01

NCGC00015971-03

NCGC00162336-01

Quelicin

Quelicin Preservative Free

SCK

ST50437287

STK177290

Scoline

Succicuran

Succinic acid, diester with choline

Succinic acid, diester with choline chloride

Succinocholine

Succinoylcholine

Succinyl choline

Succinylbischoline

Succinylcholine

Succinylcholine Chloride

Succinyldicholine

Sucostrin

Suxamethonium

Suxamethonium chloride

UNII-J2R869A8YF

ZINC01530820

succinylcholine

succinyldicholine

trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio

trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium

Mitoxantrone

approved, investigational

Phase 3

257

65271-80-9

4212

Synonyms:

1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone

1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE

1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione

1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione

1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon

1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione

1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione

1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone

1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione

137635-96-2

2fum

5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone

65271-80-9

70476-82-3

70476-82-3 (hydrochloride)

70711-41-0

70711-41-0 (acetate)

70945-62-9

9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9CI)

AB00053716

AC1L1HNY

AN-584/42007670

BIDD:PXR0181

BPBio1_000627

BRD-K21680192-300-05-2

BRD-K21680192-300-07-8

BRN 2795126

BSPBio_000569

BSPBio_003160

C11195

C22H28N4O6

CAS-70476-82-3

CCRIS 7604

CHEBI:50729

CHEMBL58

CID4212

D08224

DB01204

DHAD

DHAQ

DHAQ (*Diacetate salt*)

DHAQ HCl

Dihydroxyanthraquinone

DivK1c_000516

HMS2090D05

IDI1_000516

KBio1_000516

KBio2_002135

KBio2_004703

KBio2_007271

KBio3_002660

KBioGR_001531

KBioSS_002135

LS-20638

Liposome Encapsulated Mitoxantrone (LEM)

Lopac-M-6545

Lopac0_000779

MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE

MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE

MIX

MLS002703044

Misostol

Misostol (TN)

Mitox

Mitoxanthrone

Mitoxantron

Mitoxantrona

Mitoxantrona [INN-Spanish]

Mitoxantrone

Mitoxantrone (INN)

Mitoxantrone (free base)

Mitoxantrone 2HCl

Mitoxantrone HCl

Mitoxantrone Hydrochloride

Mitoxantrone [INN]

Mitoxantrone dihydrochloride

Mitoxantrone hydrochloride

Mitoxantronum

Mitoxantronum [INN-Latin]

Mitozantrone

Mitozantrone hydrochloride

MolPort-003-849-239

NCGC00015693-01

NCGC00015693-02

NCGC00015693-04

NCGC00162251-01

NCI60_002276

NCI60_002535

NChemBio.2007.10-comp17

NINDS_000516

NSC 279836

NSC-279836

NSC-287836

NSC-299195

NSC-301739

NSC-301739D

NSC279836

NSC299195

NSC301739

Neuro_000153

Novantron

Novantrone

Novantrone(R) (mitoxantrone for injection concentrate)

Prestwick0_000385

Prestwick1_000385

Prestwick2_000385

Prestwick3_000385

S2485_Selleck

SMP2_000179

SMR001549953

SPBio_000756

SPBio_002490

SR-01000076001

SR-01000076001-7

STK631833

Spectrum2_000908

Spectrum3_001590

Spectrum4_000866

Spectrum5_001205

Spectrum_001655

UNII-BZ114NVM5P

VU0244399-2

mitoxantrone

Niacin

approved, investigational, nutraceutical

Phase 3, Phase 2, Phase 1

361

59-67-6

938

Synonyms:

3-Carboxylpyridine

3-Carboxypyridine

3-Pyridinecarboxylate

3-Pyridinecarboxylic acid

3-Pyridylcarboxylate

3-Pyridylcarboxylic acid

3-carboxypyridine

Acide Nicotinique

Acido nicotinico

Acidum Nicotinicum

Akotin

Anti-pellagra vitamin

Apelagrin

Daskil

Efacin

Enduracin

Linic

M-Pyridinecarboxylic Acid

Niac

Niacin

Niacine

Niacor

Niaspan

Niaspan ER

Nicacid

Nicamin

Nicangin

Nico-Span

Nicobid

Nicocap

Nicodelmine

Nicolar

Niconacid

Nicosan 3

Nicotinate

Nicotinic Acid

Nicotinic acid

Nicotinipca

Nicyl

Nikotinsaeure

Nyclin

P.P. factor

PP Factor

Pellagra preventive factor

Pellagrin

Pelonin

Pyridine-beta-carboxylic acid

Slo-niacin

Vitamin B3

Wampocap

beta-Pyridinecarboxylic acid

pyridine-β-carboxylic acid

β-pyridinecarboxylic acid

Folic Acid

approved, nutraceutical

Phase 3, Phase 2, Phase 1

2924

59-30-3

6037

Synonyms:

(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid

01769_FLUKA

2d0k

33609-88-0

36653-55-1 (mono-potassium salt)

59-30-3

6484-89-5 (mono-hydrochloride salt)

AC-11682

AC1L1LNX

AI3-26387

AKOS000503224

ARONIS014410

Acfol (Spain)

Acide folique

Acide folique [INN-French]

Acido folico

Acido folico [INN-Spanish]

Acidum folicum

Acidum folicum [INN-Latin]

Acifolic

Antianemia factor

Apo-Folic

BIDD:ER0563

BIDD:GT0641

BIF0608

BPBio1_000654

BSPBio_000594

BSPBio_002338

C00504

C20H20N6O6

CAS-59-30-3

CCRIS 666

CHEBI:27470

CHEMBL1622

CID6037

CPD000471860

Cytofol

D00070

DB00158

DivK1c_000494

Dosfolat B activ

EINECS 200-419-0

F0043

F7876_SIAL

F7876_SIGMA

F8758_SIGMA

F8798_SIAL

F8890_SIGMA

FOL

Facid

Factor U

Folacid

Folacin

Folaemin

Folaemin [Netherlands]

Folan

Folasic (Australia)

Folate

Folbal

Folcidin

Folcidin (VAN)

Folcysteine

Foldine

Foldine [France]

Folettes

Foliamin

Folic

Folic Acid

Folic acid

Folic acid (JP15/USP/INN)

Folic acid (TN)

Folic acid [BAN:INN:JAN]

Folic acid [INN:BAN:JAN]

Folic acid dihydrate

Folicet

Folicet (TN)

Folico

Folico (Italy)

Folina

Folina (Italy)

Folipac

Folsaeure

Folsan

Folsaure

Folsav

Folvite

Folvron

Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L

HMS1921D20

HMS2092N17

HMS501I16

HSDB 2002

IDI1_000494

InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s

Incafolic

KBio1_000494

KBio2_001861

KBio2_004429

KBio2_006997

KBio3_001558

KBioGR_002222

KBioSS_001861

Kyselina listova

Kyselina listova [Czech]

LS-2157

Liver Lactobacillus casei factor

MLS001304016

MLS001335861

Millafol

Mission prenatal

Mittafol

MolPort-004-285-551

N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid

N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid

N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid

N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid

N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid

N-Pteroyl-L-glutamic acid

N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid

N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid

N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid

NCGC00016265-01

NCGC00142391-01

NINDS_000494

NSC 3073

Nifolin

Nifolin [Denmark]

Novofolacid

Novofolacid [Canada]

PGA

PGA (VAN)

Prestwick3_000627

Prestwick_230

PteGlu

Pteroyl-L-glutamate

Pteroyl-L-glutamic acid

Pteroyl-L-monoglutamate

Pteroyl-L-monoglutamic acid

Pteroylglutamate

Pteroylglutamic acid

Pteroylmonoglutamate

Pteroylmonoglutamic acid

SAM002264616

SDCCGMLS-0066738.P001

SMP2_000137

SMR000471860

SPBio_001357

SPECTRUM1502020

Serum Folate Level

Spectrum2_001459

Spectrum3_000749

Spectrum4_001751

Spectrum5_000602

Spectrum_001381

UNII-935E97BOY8

Usaf cb-13

Vitamin B11

Vitamin B9

Vitamin Bc

Vitamin Be

Vitamin M

bmse000299

folic acid

nchembio.108-comp10

Maleic acid

experimental

Phase 2, Phase 3, Phase 1

274

110-16-7

444972, 444266

Synonyms:

(2Z)-2-Butenedioate

(2Z)-2-Butenedioic acid

(2Z)-Butene-2-dioate

(2Z)-Butene-2-dioic acid

(2Z)-but-2-enedioate

(2Z)-but-2-enedioic acid

(Z)-2-Butenedioate

(Z)-2-Butenedioic acid

(z)-butenedioate

(z)-butenedioic acid

2-Butenedioate

2-Butenedioic acid

Cis-butenedioate

Cis-butenedioic acid

H2male

Kyselina maleinova

MAE

Maleate

Maleic acid

Maleic acid [NA2215]

Maleinic acid

Malenic acid

Malezid CM

Scotchbond multipurpose etchant

Toxilic acid

cis-1,2-Ethylenedicarboxylic acid

cis-2-Butenedioate

cis-2-Butenedioic acid

cis-But-2-enedioate

cis-But-2-enedioic acid

Docetaxel

approved, investigational, Approved May 1996

Phase 3, Phase 2, Phase 1

1844

114977-28-5

148124, 9877265

Synonyms:

(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate

(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate

01885_FLUKA

114977-28-5

4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate

4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate

AC-383

AC1L3WHJ

ANX-514

BIND-014

C11231

CHEBI:4672

CHEMBL92

CID148124

D07866

DB01248

Docefrez

Docetaxel

Docetaxel (INN)

Docetaxel anhydrous

Docetaxel, Trihydrate

EmDOC

HMS2089K08

InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5

MolPort-003-847-005

N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel

N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol

N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel

N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol

N-debenzoyl-N-Boc-10-deacetyl taxol

NSC-628503

PSMA-targeted docetaxel nanoparticle

RP-56976

SDP-014

TXL

Taxotere

Taxotere (TN)

Taxotere(R)

XRP-6976L

docetaxel

docetaxel 114977-28-5

nchembio.188-comp8

nchembio.2007.34-comp7

nchembio.573-comp11

nchembio853-comp8

Doxil

Approved June 1999

Phase 3, Phase 2, Phase 1

1582

31703

Synonyms:

Dox-SL

Doxil

Evacet

LipoDox

Pegylated Liposomal Doxorubicin Hydrochloride

liposomal doxorubicin

Anti-Bacterial Agents

Phase 3, Phase 2, Phase 1

9140

Cediranib

Phase 2, Phase 3

9933475

Synonyms:

288383-20-0

4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline

4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline

790713-41-6

AKOS005145767

AZD 2171

AZD-2171

AZD2171

AZD2171, Recentin, Cediranib

CHEMBL491473

CID9933475

Cediranib

Cediranib (USAN/INN)

Cediranib maleate

D08881

EC-000.2328

Kinome_3318

M6294

NSC-732208

Recentin

S1017_Selleck

UNII-NQU9IPY4K9

ZD-2171

cediranib

Adjuvants, Immunologic

Phase 3, Phase 2, Phase 1

1783

topoisomerase I inhibitors

Phase 2, Phase 3, Phase 1

1131

Tubulin Modulators

Phase 3, Phase 2, Phase 1

4279

Antibiotics, Antitubercular

Phase 3, Phase 2, Phase 1

5971

Interventional clinical trials:

(show top 50) (show all 367)

id	Name	Status	NCT ID	Phase
1	Interleukin-2 in Treating Patients With Metastatic Kidney Cancer	Completed	NCT00006864	Phase 4
2	Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy	Recruiting	NCT02570789	Phase 4
3	Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors	Recruiting	NCT02700568	Phase 4
4	First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma	Recruiting	NCT01521715	Phase 4
5	A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma	Recruiting	NCT02596035	Phase 4
6	Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma	Terminated	NCT00930345	Phase 4
7	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Completed	NCT00262847	Phase 3
8	Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer	Completed	NCT00006011	Phase 3
9	Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer	Completed	NCT00005583	Phase 3
10	Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer	Completed	NCT00002493	Phase 3
11	Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery	Completed	NCT00002807	Phase 3
12	Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer	Completed	NCT00006027	Phase 3
13	Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer	Completed	NCT00003749	Phase 3
14	TroVax Renal Immunotherapy Survival Trial	Completed	NCT00397345	Phase 3
15	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	Completed	NCT00483782	Phase 3
16	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3
17	Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer	Completed	NCT00002568	Phase 3
18	Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer	Completed	NCT00002717	Phase 3
19	Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer	Completed	NCT00003644	Phase 3
20	Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer	Completed	NCT00003322	Phase 3
21	Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody	Completed	NCT00606632	Phase 3
22	Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer	Completed	NCT00087022	Phase 3
23	A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy	Completed	NCT00738530	Phase 3
24	Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer	Completed	NCT00002611	Phase 3
25	Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)	Completed	NCT00072046	Phase 3
26	Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer	Completed	NCT00492258	Phase 3
27	Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer	Completed	NCT00427713	Phase 3
28	Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer	Completed	NCT00678392	Phase 3
29	GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma	Completed	NCT00495846	Phase 2, Phase 3
30	E-MOSAIC Electronic Tool to Monitor Symptoms	Completed	NCT00477919	Phase 3
31	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer	Recruiting	NCT00565851	Phase 3
32	Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	NCT02502266	Phase 2, Phase 3
33	Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	NCT00719303	Phase 3
34	Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	NCT02446600	Phase 3
35	Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol	Recruiting	NCT02501954	Phase 3
36	Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer	Recruiting	NCT01672892	Phase 3
37	Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery	Recruiting	NCT01575548	Phase 3
38	Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer	Recruiting	NCT01099423	Phase 3
39	S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery	Recruiting	NCT01120249	Phase 3
40	Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer	Recruiting	NCT01150630	Phase 2, Phase 3
41	Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer	Active, not recruiting	NCT00108745	Phase 3
42	Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer	Active, not recruiting	NCT00807768	Phase 3
43	Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer	Active, not recruiting	NCT00942357	Phase 3
44	Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer	Active, not recruiting	NCT00411138	Phase 3
45	Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	Active, not recruiting	NCT01167712	Phase 3
46	Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Active, not recruiting	NCT00951496	Phase 3
47	Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)	Active, not recruiting	NCT01668784	Phase 3
48	Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery	Active, not recruiting	NCT00326898	Phase 3
49	Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients	Active, not recruiting	NCT01599754	Phase 3
50	Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy	Active, not recruiting	NCT01198158	Phase 3

Search NIH Clinical Center for Renal Clear Cell Carcinoma

Genetic Tests for Renal Clear Cell Carcinoma

Anatomical Context for Renal Clear Cell Carcinoma

Sources:
³³MalaCards
See all MalaCards sources

MalaCards organs/tissues related to Renal Clear Cell Carcinoma:

³³

Kidney, Endothelial, Liver, Prostate, Thyroid, Breast, Lung

Animal Models for Renal Clear Cell Carcinoma or affiliated genes

Sources:
³⁸MGI
See all MalaCards sources

MGI Mouse Phenotypes related to Renal Clear Cell Carcinoma:

³⁸

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	embryo	MP:0005380	8.8	BIRC5, HIF1A, KDR, MTOR, SETD2, VEGFA
2	muscle	MP:0005369	8.6	HIF1A, HNF1A, KDR, MTOR, VEGFA, VHL
3	immune system	MP:0005387	7.4	BIRC5, FHIT, HIF1A, KDR, MME, MTOR
4	homeostasis/metabolism	MP:0005376	6.5	BIRC5, FHIT, HIF1A, HNF1A, KDR, KRT7

Publications for Renal Clear Cell Carcinoma

Sources:
⁵⁴PubMed
See all MalaCards sources

Articles related to Renal Clear Cell Carcinoma:

(show top 50) (show all 152)

id	Title	Authors	Year
1	PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma. (27100670)	Chowdhury B.... Dykhuizen E.C.	2016
2	Expression and significance of FOXP1, HIF-1a and VEGF in renal clear cell carcinoma. (25778315)	Wan L.... Wu X.	2015
3	Metastases of renal clear cell carcinoma to ovary--case report and review of the literature. (26050366)	Kostrzewa M.... WilczyA8ski J.R.	2015
4	Expression of PGAM1 in renal clear cell carcinoma and its clinical significance. (26464696)	Li C.... Mao X.	2015
5	Identification of genes and pathways involved in kidney renal clear cell carcinoma. (25559354)	Yang W.... Yang M.	2014
6	Neoadjuvant sunitinib effectiveness in T4 renal clear cell carcinoma: a case report. (25050998)	Ricciardulli S.... Celia A.	2014
7	Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project. (24454902)	Ricketts C.J.... Linehan W.M.	2014
8	Identification of angiogenesis-related miRNAs in a population of patients with renal clear cell carcinoma. (25119741)	Li H.C.... Chong T.	2014
9	The Expression and Role of MEKK3 in Renal Clear Cell Carcinoma. (25388155)	Lu H.... Gan M.	2014
10	Bilateral synchronous multifocal renal clear-cell carcinoma. (23627203)	Pothen L.... Lambert M.	2013
11	Paraneoplastic symptoms: cachexia, polycythemia, and hypercalcemia are, respectively, related to vascular endothelial growth factor (VEGF) expression in renal clear cell carcinoma. (22534085)	Ding G.X.... Ding Q.	2013
12	Multiphasic contrast-enhanced MRI: single-slice versus volumetric quantification of tumor enhancement for the assessment of renal clear-cell carcinoma fuhrman grade. (23152173)	Vargas H.A.... Akin O.	2013
13	Osteomalacia-inducing renal clear cell carcinoma uncovered by 99mTc-Hydrazinonicotinyl-Tyr3-octreotide (99mTc-HYNIC-TOC) scintigraphy. (24089059)	Jin X.... Zhuang H.	2013
14	Hypoxia-inducible factor 1I+ mediates the down-regulation of superoxide dismutase 2 in von Hippel-Lindau deficient renal clear cell carcinoma. (23611775)	Gao Y.H.... Wang L.S.	2013
15	Lower mRNA and protein expression levels of LC3 and Beclin1, markers of autophagy, were correlated with progression of renal clear cell carcinoma. (24186908)	Deng Q.... Chong T.	2013
16	Subtotal distal pancreatectomy for metachronous metastatic renal clear cell carcinoma. (23368657)	Aguayo-Albasini J.L.... Mengual-Ballester M.	2012
17	Expression and prognostic significance of Src family members in renal clear cell carcinoma. (22814579)	Qayyum T.... Edwards J.	2012
18	Correlation between hyaluronic acid,hyaluronic Acid synthase and human renal clear cell carcinoma. (23467480)	Cai J.L.... Na Y.Q.	2011
19	Stage pT3a of renal clear cell carcinoma: do tumors with sinus fat involvement behave the same as those with perinephric fat involvement? (21655644)	Chaves Portela S.... Paniagua P.	2011
20	Genetic heterogeneity and chromatin modifiers in renal clear cell carcinoma. (20528227)	Staller P.	2010
21	Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? (21102591)	Dolley-Hitze T.... Vigneau C.	2010
22	The expression and clinical significance of TGF-beta1 and MMP2 in human renal clear cell carcinoma. (19223381)	Yang S.D.... Zhou Z.Y.	2010
23	A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells. (19885558)	Jeong S.H.... Yoo Y.H.	2009
24	Microarray analysis of microRNA expression in renal clear cell carcinoma. (19443172)	Huang Y.... Zhang L.	2009
25	Contrast-enhanced ultrasound for detection and diagnosis of renal clear cell carcinoma. (19493467)	Dong X.Q.... Wang X.M.	2009
26	Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. (18359287)	Ivanov S.V.... Lerman M.I.	2008
27	Na,K-adenosine triphosphatase alpha1-subunit predicts survival of renal clear cell carcinoma. (18006011)	Seligson D.B.... Rajasekaran A.K.	2008
28	A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma. (18581596)	Cho K.S.... Hong S.J.	2008
29	Loss of PL6 protein expression in renal clear cell carcinomas and other VHL-deficient tumours. (17973242)	Ivanova A.V.... Lerman M.I.	2008
30	Computational pathology analysis of tissue microarrays predicts survival of renal clear cell carcinoma patients. (18982583)	Fuchs T.J.... Buhmann J.M.	2008
31	High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma. (17922474)	Yoshimoto T.... Moriyama M.	2007
32	Metastatic renal clear cell carcinoma in the parotid gland: a study of immunohistochemical profile and cell adhesion molecules (CAMs) expression in two cases. (17607380)	Andreadis D.... Barbatis C.	2007
33	Transient massive peripheral blood blastosis in patient with renal clear-cell carcinoma after treatment with high-dose recombinant interleuklin-2. (17329199)	del Mar Osma M.... Vicente V.	2007
34	Solitary metachronous metastasis to the thyroid from renal clear cell carcinoma 19 years after nephrectomy: report of a case. (15912297)	Wada N.... Takanashi Y.	2005
35	Diffuse expression of MUC 1 in metastases of renal clear cell carcinoma as a possible therapeutic target for renal cancer. (16178902)	Leroy X.... Copin M.C.	2005
36	Expression of CD10 and cytokeratins in ovarian and renal clear cell carcinoma. (15968199)	Ohta Y.... Ota H.	2005
37	Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma. (14767340)	Kurose K.... Huh N.H.	2004
38	Somatic mutations of VHL gene and HIF-1alpha expression in primary renal clear cell carcinomas]. (15062033)	Guo H.F.... Na Y.Q.	2004
39	Differentiation of renal clear cell carcinoma and renal papillary carcinoma using quantitative CT enhancement parameters. (15505308)	Ruppert-Kohlmayr A.J.... Ruppert G.	2004
40	Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. (15126876)	Bui M.H.... Belldegrun A.S.	2004
41	Metastatic renal clear cell carcinoma mimicking stage IV lung cancer. (14620276)	Griniatsos J.... Bastounis E.	2003
42	Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. (12576453)	Bui M.H.... Belldegrun A.S.	2003
43	Fatty metastatic lesions in 2 patients with renal clear-cell carcinoma. (14600452)	Muram T.M.... Aisen A.	2003
44	Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. (12434420)	Currie M.J.... Fox S.B.	2002
45	Type I 5'-iodothyronine deiodinase activity and mRNA are remarkably reduced in renal clear cell carcinoma. (11383912)	Pachucki J.... Nauman A.	2001
46	Thyroid metastases from renal clear cell carcinoma: a cyto-histological study of two cases. (11753829)	Ambrosiani L.... Bianchi A.	2001
47	Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. (10590373)	Gilcrease M.Z.... Albores-Saavedra J.	1999
48	ELECTRON MICROSCOPIC OBSERVATIONS ON SPECIALIZATIONS OF THE CELL SURFACE IN RENAL CLEAR CELL CARCINOMA. (14279879)	Seljelid R.... Ericsson J.L.	1965
49	(23273174)
50	(18199565)

Genes related to Renal Clear Cell Carcinoma

Sources:
²⁰GeneCards, ⁷Cosmic, ⁵Clinvar, ¹²DISEASES, ⁴⁷Novoseek, ⁵¹Orphanet
See all MalaCards sources

Genes related to Renal Clear Cell Carcinoma (11 elite genes):

(show all 21)

- Elite gene

- Cancer Census gene in COSMIC

id	Symbol	Description	Score	Implication	PubmedIds
1	HNF1A	HNF1 Homeobox A	400.00	Pathogenic ⁵
2	VHL	Von Hippel-Lindau Tumor Suppressor	36.64	DISEASES inferred ¹² Novoseek inferred ⁴⁷ GeneCards inferred via : Publications (show sections)	18660794, 15062033, 17255293 more 18464292, 11798864, 9891082, 10766184, 12883707, 15809750, 11431362, 8718521, 15100736, 9652757, 15180922, 16643849, 20022054, 7585510, 15217953, 13679920, 11406557, 11237528, 11024059, 7881415, 11390984, 10475065, 11536052, 10096566, 9443397, 19759417, 18039096, 18043042, 16107702, 9671762, 8855222, 19073886, 18359287, 15893810, 17598890, 16510593, 16983094, 16849532, 14612498, 12944410, 12673678, 11278694, 17205537, 8187067, 10535940, 20054297, 16585196, 15448018, 12359370
3	HIF1A	Hypoxia Inducible Factor 1 Alpha Subunit	32.83	DISEASES inferred ¹² Novoseek inferred ⁴⁷ GeneCards inferred via : Publications (show sections)	11431362, 15062033, 16600797 more 17064593, 15854350, 16854277, 15184875, 20032376, 18094421, 18043042, 18547492
4	VEGFA	Vascular Endothelial Growth Factor A	32.31	DISEASES inferred ¹² Novoseek inferred ⁴⁷ GeneCards inferred via : Publications (show sections)	17270362, 17255293, 18547492 more 15569457, 14550470, 18695901, 20021866, 16854277, 18635227, 9652757, 17160391, 20194016, 19671223, 17362927, 16145371, 19402074, 17382701, 19683801, 19302703, 20022054, 19731255, 10475065, 11156212, 17340158
5	SETD2	SET Domain Containing 2	30.99	DISEASES inferred ¹² Novoseek inferred ⁴⁷ GeneCards inferred via : Publications (show sections)	16515534, 15220362, 16510593 more 17551816
6	MME	Membrane Metallo-Endopeptidase	30.09	DISEASES inferred ¹² Novoseek inferred ⁴⁷ GeneCards inferred via : Publications (show sections)	15578072, 15286660, 17374232
7	MUC1	Mucin 1, Cell Surface Associated	28.85	DISEASES inferred ¹² Novoseek inferred ⁴⁷ GeneCards inferred via : Publications (show sections)	12010365, 17374232
8	MTOR	Mechanistic Target Of Rapamycin	27.44	DISEASES inferred ¹² Novoseek inferred ⁴⁷ GeneCards inferred via : Publications (show sections)	17162089, 20022054
9	VIM	Vimentin	25.90	Novoseek inferred ⁴⁷ GeneCards inferred via : Publications (show sections)	12819395, 17374232, 11293161 more 15132851
10	CA9	Carbonic Anhydrase 9	25.01	DISEASES inferred ¹² Novoseek inferred ⁴⁷ GeneCards inferred via : Publications (show sections)	19539328, 17382701, 15126876 more 17947723, 18695901, 18300814, 12576453, 18669473, 19963243, 18565906, 20224781, 20431476, 17095063, 15500003, 19695674, 18669472
11	TMEM127	Transmembrane Protein 127	25.00	Susceptibility factor ⁵¹
12	KDR	Kinase Insert Domain Receptor	24.78	Novoseek inferred ⁴⁷ GeneCards inferred via : Variants (show sections)	20194016, 16145371
13	MUC3A	Mucin 3A, Cell Surface Associated	24.66	Novoseek inferred ⁴⁷ GeneCards inferred via : Publications (show sections)	14550470, 12010365
14	BIRC5	Baculoviral IAP Repeat Containing 5	24.62	Novoseek inferred ⁴⁷ GeneCards inferred via : Publications (show sections)	18538369, 19296514, 19219613 more 16736510
15	TCEB2	Transcription Elongation Factor B Subunit 2	22.69	DISEASES inferred ¹² Novoseek inferred ⁴⁷ GeneCards inferred via : Publications (show sections)	9652757
16	KRT7	Keratin 7	21.96	DISEASES inferred ¹² Novoseek inferred ⁴⁷ GeneCards inferred via : Publications (show sections)	15502805, 12819395, 17374232 more 18042078, 18604734, 17210525, 15132851
17	TCEB1	Transcription Elongation Factor B Subunit 1	14.16	DISEASES inferred ¹² GeneCards inferred via : Publications (show sections)
18	CUL2	Cullin 2	14.12	DISEASES inferred ¹² GeneCards inferred via : Publications (show sections)
19	SPAG4	Sperm Associated Antigen 4	13.95	DISEASES inferred ¹² GeneCards inferred via : Publications (show sections)
20	FHIT	Fragile Histidine Triad	13.88	DISEASES inferred ¹² Novoseek inferred ⁴⁷	18378390, 11920739, 9679951 more 11390984, 10096566, 10571505, 10530564, 11406557
21	EPB41L3	Erythrocyte Membrane Protein Band 4.1 Like 3	13.53	DISEASES inferred ¹² GeneCards inferred via : Publications (show sections)

Variations for Renal Clear Cell Carcinoma

Sources:
⁵Clinvar, ⁷Cosmic
See all MalaCards sources

Clinvar genetic disease variations for Renal Clear Cell Carcinoma:

⁵

id	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	HNF1A	NM_000545.6(HNF1A): c.872dupC (p.Gly292Argfs)	duplication	Pathogenic	rs587776825	GRCh37	Chr 12, 121432125: 121432125

Cosmic variations for Renal Clear Cell Carcinoma:

⁷ (show top 50) (show all 759)

id	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Conf
1	COSM25654	CDC5L	kidney,NS,carcinoma,clear cell	22
2	COSM26594	RNF144A	kidney,NS,carcinoma,clear cell	22
3	COSM26987	RGS7	kidney,NS,carcinoma,clear cell	22
4	COSM27269	UMPS	kidney,NS,carcinoma,clear cell	22
5	COSM27618	KMT2A	kidney,NS,carcinoma,clear cell	22
6	COSM30474	TRIO	kidney,NS,carcinoma,clear cell	22
7	COSM30502	ITPR3	kidney,NS,carcinoma,clear cell	22
8	COSM520	KRAS	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
9	COSM549	KRAS	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
10	COSM580	NRAS	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
11	COSM760	PIK3CA	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
12	COSM775	PIK3CA	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
13	COSM5036	PTEN	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
14	COSM5181	PTEN	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
15	COSM5196	PTEN	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
16	COSM6549	TP53	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
17	COSM10647	TP53	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
18	COSM10648	TP53	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
19	COSM10659	TP53	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
20	COSM10663	TP53	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
21	COSM10690	TP53	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
22	COSM10733	TP53	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
23	COSM10738	TP53	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
24	COSM10863	TP53	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
25	COSM10891	TP53	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
26	COSM11133	TP53	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
27	COSM11524	TP53	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
28	COSM13440	CDKN2A	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
29	COSM14289	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
30	COSM14290	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
31	COSM14301	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
32	COSM14305	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
33	COSM14306	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
34	COSM14309	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
35	COSM14311	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
36	COSM14312	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
37	COSM14318	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
38	COSM14319	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
39	COSM14320	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
40	COSM14321	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
41	COSM14322	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
42	COSM14323	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
43	COSM14325	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
44	COSM14328	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
45	COSM14344	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
46	COSM14348	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
47	COSM14350	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
48	COSM14356	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
49	COSM14362	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13
50	COSM14363	VHL	kidney,NS,carcinoma,clear cell renal cell carcinoma	13

Expression for genes affiliated with Renal Clear Cell Carcinoma

Sources:
¹⁷Gene Expression Omnibus DataSets
See all MalaCards sources

Search GEO for disease gene expression data for Renal Clear Cell Carcinoma.

Pathways for genes affiliated with Renal Clear Cell Carcinoma

Sources:
⁵²PathCards, ⁵⁷Reactome, ³⁹NCBI BioSystems Database, ³¹KEGG, ⁵⁵QIAGEN, ⁶²Thomson Reuters
See all MalaCards sources

Pathways related to Renal Clear Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 12)

id	Super pathways	Score	Top Affiliating Genes
1	VEGF ligand-receptor interactions⁵⁷ Show member pathways VEGF binds to VEGFR leading to receptor dimerization⁵⁷	10.0	KDR, VEGFA
2	HIF-1-alpha transcription factor network³⁹	9.8	CA9, HIF1A, VEGFA
3	Angiogenesis³⁹	9.8	HIF1A, KDR, VEGFA
4	Signaling events mediated by VEGFR1 and VEGFR2³⁹ Show member pathways VEGFR1 specific signals³⁹	9.6	HIF1A, KDR, VEGFA, VHL
5	Proteoglycans in cancer³¹	9.5	HIF1A, KDR, MTOR, VEGFA
6	Hypoxic and oxygen homeostasis regulation of HIF-1-alpha³⁹	8.7	CUL2, HIF1A, TCEB1, TCEB2, VHL
7	HIF1Alpha Pathway⁵⁵	8.5	CUL2, HIF1A, TCEB1, TCEB2, VEGFA, VHL
8	HIF-1 signaling pathway³¹	8.3	CUL2, HIF1A, MTOR, TCEB1, TCEB2, VEGFA
9	Development HGF signaling pathway⁶² Show member pathways Neurotrophin signaling pathway³¹ Apoptosis and survival NGF signaling pathway⁶² Development Neurotrophin family signaling⁶² Renal cell carcinoma³¹ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)³⁹ Apoptosis and survival Role of CDK5 in neuronal death and survival⁶² Signaling of Hepatocyte Growth Factor Receptor³⁹ Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1⁶²	8.3	CUL2, HIF1A, MTOR, TCEB1, TCEB2, VEGFA
10	Cellular Senescence⁵⁷ Show member pathways Cellular responses to stress⁵⁷ Oxidative Stress Induced Senescence⁵⁷ Senescence-Associated Secretory Phenotype (SASP)⁵⁷	8.0	CA9, CUL2, HIF1A, MTOR, TCEB1, TCEB2
11	Cellular response to hypoxia⁵⁷ Show member pathways HIF-2-alpha transcription factor network³⁹ Regulation of Hypoxia-inducible Factor (HIF) by oxygen⁵⁷ Regulation of gene expression by Hypoxia-inducible Factor⁵⁷ Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha⁵⁷	8.0	CA9, CUL2, HIF1A, KDR, TCEB1, TCEB2
12	Pathways in cancer³¹	8.0	BIRC5, CUL2, HIF1A, MTOR, TCEB1, TCEB2

GO Terms for genes affiliated with Renal Clear Cell Carcinoma

Sources:
¹⁸Gene Ontology
See all MalaCards sources

Biological processes related to Renal Clear Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 11)

id	Name	GO ID	Score	Top Affiliating Genes
1	cell migration involved in sprouting angiogenesis	GO:0002042	10.6	KDR, VEGFA
2	positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway	GO:0038033	10.5	KDR, VEGFA
3	positive regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:0061419	10.5	HIF1A, VEGFA
4	positive regulation of macroautophagy	GO:0016239	10.5	HIF1A, KDR
5	maternal process involved in female pregnancy	GO:0060135	10.4	HIF1A, MTOR
6	vasculogenesis	GO:0001570	9.9	KDR, SETD2, VEGFA
7	positive regulation of neuroblast proliferation	GO:0002052	9.8	HIF1A, VEGFA
8	regulation of transcription from RNA polymerase II promoter	GO:0006357	9.8	HNF1A, TCEB1, VEGFA
9	regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:0061418	9.6	HIF1A, TCEB1, TCEB2, VEGFA
10	negative regulation of apoptotic process	GO:0043066	9.1	BIRC5, HIF1A, KDR, VEGFA, VHL
11	cellular response to hypoxia	GO:0071456	8.3	CUL2, HIF1A, MTOR, TCEB1, TCEB2, VEGFA